

6 Literature

- 1 **Bataille, R. and Harousseau, J. L.**, Multiple myeloma. *N Engl J Med* 1997. **336**: 1657-1664.
- 2 **Malpas, J. S., Bergsagel, D. E., Kyle, R. & Anderson, K.**, *Multiple Myeloma: Biology and Management*. Oxford Univ. Press, Oxford: 1998.
- 3 **Kuehl, W. M. and Bergsagel, P. L.**, Multiple myeloma: evolving genetic events and host interactions. *Nat Rev Cancer* 2002. **2**: 175-187.
- 4 **Tricot, G.**, Multiple Myeloma and Other Plasma Cell Disorders. In **Hoffman, B., Shattil, Furie, Cohen, Silberstein, and McGlave** (Ed.) *Hematology: Basic Principles and Practice*. Churchill-Livingstone 2000, pp 1398-1416.
- 5 **Hallek, M., Bergsagel, P. L. and Anderson, K. C.**, Multiple myeloma: increasing evidence for a multistep transformation process. *Blood* 1998. **91**: 3-21.
- 6 **Riedel, D. A. and Pottern, L. M.**, The epidemiology of multiple myeloma. *Hematol Oncol Clin North Am* 1992. **6**: 225-247.
- 7 **Kyle, R. A. and Rajkumar, S. V.**, Monoclonal gammopathies of undetermined significance. *Hematol Oncol Clin North Am* 1999. **13**: 1181-1202.
- 8 **Salmon, S. E. and Seligmann, M.**, B-cell neoplasia in man. *Lancet* 1974. **2**: 1230-1233.
- 9 **Kyle, R. A. and Rajkumar, S. V.**, Multiple myeloma. *N Engl J Med* 2004. **351**: 1860-1873.
- 10 **Durie, B. G.**, Multiple myeloma: what's new. *CA Cancer J Clin* 2001. **51**: 271-272, 263.
- 11 **Shapiro-Shelef, M. and Calame, K.**, Plasma cell differentiation and multiple myeloma. *Curr Opin Immunol* 2004. **16**: 226-234.
- 12 **Shapiro-Shelef, M. and Calame, K.**, Regulation of plasma-cell development. *Nat Rev Immunol* 2005. **5**: 230-242.
- 13 **O'Connor, B. P., Gleeson, M. W., Noelle, R. J. and Erickson, L. D.**, The rise and fall of long-lived humoral immunity: terminal differentiation of plasma cells in health and disease. *Immunol Rev* 2003. **194**: 61-76.
- 14 **Anderson, K. C., Kyle, R. A., Dalton, W. S., Landowski, T., Shain, K., Jove, R., Hazlehurst, L. and Berenson, J.**, Multiple Myeloma: New Insights and Therapeutic Approaches. *Hematology (Am Soc Hematol Educ Program)* 2000: 147-165.
- 15 **Matsui, W., Huff, C. A., Wang, Q., Malehorn, M. T., Barber, J., Tanhehco, Y., Smith, B. D., Civin, C. I. and Jones, R. J.**, Characterization of clonogenic multiple myeloma cells. *Blood* 2004. **103**: 2332-2336.
- 16 **Pratt, G.**, Molecular aspects of multiple myeloma. *Mol Pathol* 2002. **55**: 273-283.
- 17 **Nishida, K., Tamura, A., Nakazawa, N., Ueda, Y., Abe, T., Matsuda, F., Kashima, K. and Taniwaki, M.**, The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. *Blood* 1997. **90**: 526-534.
- 18 **Ludwig, H.**, Advances in biology and treatment of multiple myeloma. *Ann Oncol* 2005. **16 Suppl 2**: ii106-112.
- 19 **Roodman, G. D.**, Role of the bone marrow microenvironment in multiple myeloma. *J Bone Miner Res* 2002. **17**: 1921-1925.
- 20 **Bruno, B., Giaccone, L., Rotta, M., Anderson, K. and Boccadoro, M.**, Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside. *Leukemia* 2005. **19**: 1729-1738.
- 21 **Anderson, K. C., Park, E. K., Bates, M. P., Leonard, R. C., Hardy, R., Schlossman, S. F. and Nadler, L. M.**, Antigens on human plasma cells identified by monoclonal antibodies. *J Immunol* 1983. **130**: 1132-1138.
- 22 **Berenson, J. R., Vescio, R. A. and Said, J.**, Multiple myeloma: the cells of origin--a two-way street. *Leukemia* 1998. **12**: 121-127.
- 23 **Robillard, N., Jego, G., Pellat-Deceunynck, C., Pineau, D., Puthier, D., Mellerin, M. P., Barille, S., Rapp, M. J., Harousseau, J. L., Amiot, M. and Bataille, R.**, CD28, a marker associated with tumoral expansion in multiple myeloma. *Clin Cancer Res* 1998. **4**: 1521-1526.
- 24 **Brossart, P., Schneider, A., Dill, P., Schammann, T., Grunebach, F., Wirths, S., Kanz, L., Buhning, H. J. and Brugger, W.**, The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. *Cancer Res* 2001. **61**: 6846-6850.
- 25 **Treon, S. P., Mollick, J. A., Urashima, M., Teoh, G., Chauhan, D., Ogata, A., Raje, N., Hilgers, J. H., Nadler, L., Belch, A. R., Pilarski, L. M. and Anderson, K. C.**, Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone. *Blood* 1999. **93**: 1287-1298.
- 26 **Terstappen, L. W., Johnsen, S., Segers-Nolten, I. M. and Loken, M. R.**, Identification and characterization of plasma cells in normal human bone marrow by high-resolution flow cytometry. *Blood* 1990. **76**: 1739-1747.

-
- 27 **Moscinski, L. C. and Ballester, O. F.**, Recent progress in multiple myeloma. *Hematol Oncol* 1994. **12**: 111-123.
- 28 **Anderson, K. C., Bates, M. P., Slaughenhaupt, B., Schlossman, S. F. and Nadler, L. M.**, A monoclonal antibody with reactivity restricted to normal and neoplastic plasma cells. *J Immunol* 1984. **132**: 3172-3179.
- 29 **Gonchoroff, N. J., Katzmann, J. A., Garton, J. P., Ruiz-Arguelles, G. J., Eilers, C. R., Greipp, P. R. and Kyle, R. A.**, A monoclonal antibody reactive with a subset of human plasma cells. *Br J Haematol* 1986. **62**: 619-630.
- 30 **Tazzari, P. L., Gobbi, M., Dinota, A., Bontadini, A., Grassi, G., Cerato, C., Cavo, M., Pileri, S., Caligaris-Cappio, F. and Tura, S.**, Normal and neoplastic plasma cell membrane phenotype: studies with new monoclonal antibodies. *Clin Exp Immunol* 1987. **70**: 192-200.
- 31 **Tong, A. W., Lee, J. C. and Stone, M. J.**, Characterization of a monoclonal antibody having selective reactivity with normal and neoplastic plasma cells. *Blood* 1987. **69**: 238-245.
- 32 **Huang, N., Kawano, M. M., Harada, H., Harada, Y., Sakai, A., Kuramoto, A. and Niwa, O.**, Heterogeneous expression of a novel MPC-1 antigen on myeloma cells: possible involvement of MPC-1 antigen in the adhesion of mature myeloma cells to bone marrow stromal cells. *Blood* 1993. **82**: 3721-3729.
- 33 **Ozaki, S., Kosaka, M., Harada, M., Nishitani, H., Odomi, M. and Matsumoto, T.**, Radioimmuno-detection of human myeloma xenografts with a monoclonal antibody directed against a plasma cell specific antigen, HM1.24. *Cancer* 1998. **82**: 2184-2190.
- 34 **Ozaki, S., Kosaka, M., Wakatsuki, S., Abe, M., Koishihara, Y. and Matsumoto, T.**, Immunotherapy of multiple myeloma with a monoclonal antibody directed against a plasma cell-specific antigen, HM1.24. *Blood* 1997. **90**: 3179-3186.
- 35 **Ozaki, S., Kosaka, M., Wakahara, Y., Ozaki, Y., Tsuchiya, M., Koishihara, Y., Goto, T. and Matsumoto, T.**, Humanized anti-HM1.24 antibody mediates myeloma cell cytotoxicity that is enhanced by cytokine stimulation of effector cells. *Blood* 1999. **93**: 3922-3930.
- 36 **Ohtomo, T., Sugamata, Y., Ozaki, Y., Ono, K., Yoshimura, Y., Kawai, S., Koishihara, Y., Ozaki, S., Kosaka, M., Hirano, T. and Tsuchiya, M.**, Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. *Biochem Biophys Res Commun* 1999. **258**: 583-591.
- 37 **Rew, S. B., Peggs, K., Sanjuan, I., Pizzey, A. R., Koishihara, Y., Kawai, S., Kosaka, M., Ozaki, S., Chain, B. and Yong, K. L.**, Generation of potent antitumor CTL from patients with multiple myeloma directed against HM1.24. *Clin Cancer Res* 2005. **11**: 3377-3384.
- 38 **Jalili, A., Ozaki, S., Hara, T., Shibata, H., Hashimoto, T., Abe, M., Nishioka, Y. and Matsumoto, T.**, Induction of HM1.24 peptide-specific cytotoxic T lymphocytes by using peripheral-blood stem-cell harvests in patients with multiple myeloma. *Blood* 2005. **106**: 3538-3545.
- 39 **Goto, T., Kennel, S. J., Abe, M., Takishita, M., Kosaka, M., Solomon, A. and Saito, S.**, A novel membrane antigen selectively expressed on terminally differentiated human B cells. *Blood* 1994. **84**: 1922-1930.
- 40 **Chiriva-Internati, M., Liu, Y., Weidanz, J. A., Grizzi, F., You, H., Zhou, W., Bumm, K., Barlogie, B., Mehta, J. L. and Hermonat, P. L.**, Testing recombinant adeno-associated virus-gene loading of dendritic cells for generating potent cytotoxic T lymphocytes against a prototype self-antigen, multiple myeloma HM1.24. *Blood* 2003. **102**: 3100-3107.
- 41 **Greiner, A., Neumann, M., Stingl, S., Wassink, S., Marx, A., Riechert, F. and Muller-Hermelink, H. K.**, Characterization of Wue-1, a novel monoclonal antibody that stimulates the growth of plasmacytoma cell lines. *Virchows Arch* 2000. **437**: 372-379.
- 42 **Dalton, W. S.**, Mechanisms of drug resistance in hematologic malignancies. *Semin Hematol* 1997. **34**: 3-8.
- 43 **Kuriakose, P.**, Targeted therapy for hematologic malignancies. *Cancer Control* 2005. **12**: 82-90.
- 44 **Hideshima, T., Chauhan, D., Richardson, P. and Anderson, K. C.**, Identification and validation of novel therapeutic targets for multiple myeloma. *J Clin Oncol* 2005. **23**: 6345-6350.
- 45 **Anderson, K. C., Shaughnessy, J. D., Jr., Barlogie, B., Harousseau, J. L. and Roodman, G. D.**, Multiple myeloma. *Hematology (Am Soc Hematol Educ Program)* 2002: 214-240.
- 46 **Harousseau, J. L., Shaughnessy, J., Jr. and Richardson, P.**, Multiple myeloma. *Hematology (Am Soc Hematol Educ Program)* 2004: 237-256.
- 47 **van Baren, N., Brasseur, F., Godelaine, D., Hames, G., Ferrant, A., Lehmann, F., Andre, M., Ravoet, C., Doyen, C., Spagnoli, G. C., Bakkus, M., Thielemans, K. and Boon, T.**, Genes encoding tumor-specific antigens are expressed in human myeloma cells. *Blood* 1999. **94**: 1156-1164.
- 48 **Chiriva-Internati, M., Wang, Z., Xue, Y., Bumm, K., Hahn, A. B. and Lim, S. H.**, Sperm protein 17 (Sp17) in multiple myeloma: opportunity for myeloma-specific donor T cell infusion to enhance graft-versus-myeloma effect without increasing graft-versus-host disease risk. *Eur J Immunol* 2001. **31**: 2277-2283.

-
- 49 **Vonderheide, R. H., Hahn, W. C., Schultze, J. L. and Nadler, L. M.**, The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. *Immunity* 1999. **10**: 673-679.
- 50 **Martinelli, G., Tosi, P., Ottaviani, E., Soverini, S. and Tura, S.**, Molecular therapy for multiple myeloma. *Haematologica* 2001. **86**: 908-917.
- 51 **Harrison, S. J. and Cook, G.**, Immunotherapy in multiple myeloma--possibility or probability? *Br J Haematol* 2005. **130**: 344-362.
- 52 **Ruffini, P. A., Biragyn, A. and Kwak, L. W.**, Recent advances in multiple myeloma immunotherapy. *Biomed Pharmacother* 2002. **56**: 129-132.
- 53 **Ruffini, P. A., Neelapu, S. S., Kwak, L. W. and Biragyn, A.**, Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines. *Haematologica* 2002. **87**: 989-1001.
- 54 **Holliger, P. and Hudson, P. J.**, Engineered antibody fragments and the rise of single domains. *Nat Biotechnol* 2005. **23**: 1126-1136.
- 55 **Adams, G. P. and Weiner, L. M.**, Monoclonal antibody therapy of cancer. *Nat Biotechnol* 2005. **23**: 1147-1157.
- 56 **Treon, S. P., Agus, T. B., Link, B., Rodrigues, G., Molina, A., Lacy, M. Q., Fisher, D. C., Emmanouilides, C., Richards, A. I., Clark, B., Lucas, M. S., Schlossman, R., Schenkein, D., Lin, B., Kimby, E., Anderson, K. C. and Byrd, J. C.**, CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia. *J Immunother* 2001. **24**: 272-279.
- 57 **Musto, P., Carella, A. M., Jr., Greco, M. M., Falcone, A., Sanpaolo, G., Bodenizza, C., Cascavilla, N., Melillo, L. and Carella, A. M.**, Short progression-free survival in myeloma patients receiving rituximab as maintenance therapy after autologous transplantation. *Br J Haematol* 2003. **123**: 746-747.
- 58 **Lim, S. H., Zhang, Y., Wang, Z., Varadarajan, R., Periman, P. and Esler, W. V.**, Rituximab administration following autologous stem cell transplantation for multiple myeloma is associated with severe IgM deficiency. *Blood* 2004. **103**: 1971-1972.
- 59 **Stevenson, F. K., Bell, A. J., Cusack, R., Hamblin, T. J., Slade, C. J., Spellerberg, M. B. and Stevenson, G. T.**, Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody. *Blood* 1991. **77**: 1071-1079.
- 60 **Ellis, J. H., Barber, K. A., Tutt, A., Hale, C., Lewis, A. P., Glennie, M. J., Stevenson, G. T. and Crowe, J. S.**, Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma. *J Immunol* 1995. **155**: 925-937.
- 61 **Tai, Y. T., Li, X., Tong, X., Santos, D., Otsuki, T., Catley, L., Tournilhac, O., Podar, K., Hideshima, T., Schlossman, R., Richardson, P., Munshi, N. C., Luqman, M. and Anderson, K. C.**, Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. *Cancer Res* 2005. **65**: 5898-5906.
- 62 **Tai, Y. T., Catley, L. P., Mitsiades, C. S., Burger, R., Podar, K., Shringpaure, R., Hideshima, T., Chauhan, D., Hamasaki, M., Ishitsuka, K., Richardson, P., Treon, S. P., Munshi, N. C. and Anderson, K. C.**, Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. *Cancer Res* 2004. **64**: 2846-2852.
- 63 **Maloney, D. G., Donovan, K. and Hamblin, T. J.**, Antibody therapy for treatment of multiple myeloma. *Semin Hematol* 1999. **36**: 30-33.
- 64 **Treon, S. P., Raje, N. and Anderson, K. C.**, Immunotherapeutic strategies for the treatment of plasma cell malignancies. *Semin Oncol* 2000. **27**: 598-613.
- 65 **Dhodapkar, K. M., Krasovsky, J., Williamson, B. and Dhodapkar, M. V.**, Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. *J Exp Med* 2002. **195**: 125-133.
- 66 **Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X. and Rosenberg, S. A.**, A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. *N Engl J Med* 2003. **349**: 427-434.
- 67 **Li, Y., Bendandi, M., Deng, Y., Dunbar, C., Munshi, N., Jagannath, S., Kwak, L. W. and Lyerly, H. K.**, Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells. *Blood* 2000. **96**: 2828-2833.
- 68 **Wu, A. M. and Senter, P. D.**, Arming antibodies: prospects and challenges for immunoconjugates. *Nat Biotechnol* 2005. **23**: 1137-1146.
- 69 **Karpovsky, B., Titus, J. A., Stephany, D. A. and Segal, D. M.**, Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fc gamma receptor antibodies. *J Exp Med* 1984. **160**: 1686-1701.

-
- 70 **Perez, P., Hoffman, R. W., Shaw, S., Bluestone, J. A. and Segal, D. M.,** Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. *Nature* 1985. **316**: 354-356.
- 71 **Staerz, U. D., Kanagawa, O. and Bevan, M. J.,** Hybrid antibodies can target sites for attack by T cells. *Nature* 1985. **314**: 628-631.
- 72 **Kufer, P., Lutterbuse, R. and Baeuerle, P. A.,** A revival of bispecific antibodies. *Trends Biotechnol* 2004. **22**: 238-244.
- 73 **Mack, M., Riethmuller, G. and Kufer, P.,** A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. *Proc Natl Acad Sci U S A* 1995. **92**: 7021-7025.
- 74 **Mack, M., Gruber, R., Schmidt, S., Riethmuller, G. and Kufer, P.,** Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity. *J Immunol* 1997. **158**: 3965-3970.
- 75 **Kufer, P., Mack, M., Gruber, R., Lutterbuse, R., Zettl, F. and Riethmuller, G.,** Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer. *Cancer Immunol Immunother* 1997. **45**: 193-197.
- 76 **Loffler, A., Kufer, P., Lutterbuse, R., Zettl, F., Daniel, P. T., Schwenkenbecher, J. M., Riethmuller, G., Dorken, B. and Bargou, R. C.,** A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. *Blood* 2000. **95**: 2098-2103.
- 77 **Dreier, T., Lorenczewski, G., Brandl, C., Hoffmann, P., Syring, U., Hanakam, F., Kufer, P., Riethmuller, G., Bargou, R. and Baeuerle, P. A.,** Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. *Int J Cancer* 2002. **100**: 690-697.
- 78 **Dreier, T., Baeuerle, P. A., Fichtner, I., Grun, M., Schlereth, B., Lorenczewski, G., Kufer, P., Lutterbuse, R., Riethmuller, G., Gjorstrup, P. and Bargou, R. C.,** T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct. *J Immunol* 2003. **170**: 4397-4402.
- 79 **Loffler, A., Gruen, M., Wuchter, C., Schriever, F., Kufer, P., Dreier, T., Hanakam, F., Baeuerle, P. A., Bommert, K., Karawajew, L., Dorken, B. and Bargou, R. C.,** Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. *Leukemia* 2003. **17**: 900-909.
- 80 **Gruen, M., Bommert, K. and Bargou, R. C.,** T-cell-mediated lysis of B cells induced by a CD19xCD3 bispecific single-chain antibody is perforin dependent and death receptor independent. *Cancer Immunol Immunother* 2004. **53**: 625-632.
- 81 **Schlereth, B., Quadt, C., Dreier, T., Kufer, P., Lorenczewski, G., Prang, N., Brandl, C., Lippold, S., Cobb, K., Brasky, K., Leo, E., Bargou, R., Murthy, K. and Baeuerle, P. A.,** T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. *Cancer Immunol Immunother* 2005: 1-12.
- 82 **Honemann, D., Kufer, P., Rimpler, M. M., Chatterjee, M., Friedl, S., Riecher, F., Bommert, K., Dorken, B. and Bargou, R. C.,** A novel recombinant bispecific single-chain antibody, bscWue-1 x CD3, induces T-cell-mediated cytotoxicity towards human multiple myeloma cells. *Leukemia* 2004. **18**: 636-644.
- 83 **Abken, H., Hombach, A. and Heuser, C.,** Immune response manipulation: recombinant immunoreceptors endow T-cells with predefined specificity. *Curr Pharm Des* 2003. **9**: 1992-2001.
- 84 **Abken, H., Hombach, A., Reinhold, U. and Ferrone, S.,** Can combined T-cell- and antibody-based immunotherapy outsmart tumor cells? *Immunol Today* 1998. **19**: 2-5.
- 85 **Hombach, A., Heuser, C. and Abken, H.,** The recombinant T cell receptor strategy: insights into structure and function of recombinant immunoreceptors on the way towards an optimal receptor design for cellular immunotherapy. *Curr Gene Ther* 2002. **2**: 211-226.
- 86 **Mansoor, W., Gilham, D. E., Thistlethwaite, F. C. and Hawkins, R. E.,** Engineering T cells for cancer therapy. *Br J Cancer* 2005. **93**: 1085-1091.
- 87 **Thistlethwaite, F., Mansoor, W., Gilham, D. E. and Hawkins, R. E.,** Engineering T-cells with antibody-based chimeric receptors for effective cancer therapy. *Curr Opin Mol Ther* 2005. **7**: 48-55.
- 88 **Hombach, A., Wiczarkowicz, A., Marquardt, T., Heuser, C., Usai, L., Pohl, C., Seliger, B. and Abken, H.,** Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule. *J Immunol* 2001. **167**: 6123-6131.
- 89 **Heuser, C., Hombach, A., Losch, C., Manista, K. and Abken, H.,** T-cell activation by recombinant immunoreceptors: impact of the intracellular signalling domain on the stability of receptor expression and antigen-specific activation of grafted T cells. *Gene Ther* 2003. **10**: 1408-1419.

-
- 90 **Abken, H., Hombach, A., Heuser, C., Kronfeld, K. and Seliger, B.**, Tuning tumor-specific T-cell activation: a matter of costimulation? *Trends Immunol* 2002. **23**: 240-245.
- 91 **Hombach, A., Sent, D., Schneider, C., Heuser, C., Koch, D., Pohl, C., Seliger, B. and Abken, H.**, T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis. *Cancer Res* 2001. **61**: 1976-1982.
- 92 **Hombach, A., Mucho, J. M., Gerken, M., Gellrich, S., Heuser, C., Pohl, C., Sterry, W. and Abken, H.**, T cells engrafted with a recombinant anti-CD30 receptor target autologous CD30(+) cutaneous lymphoma cells. *Gene Ther* 2001. **8**: 891-895.
- 93 **Hombach, A., Schneider, C., Sent, D., Koch, D., Willemsen, R. A., Diehl, V., Kruis, W., Bolhuis, R. L., Pohl, C. and Abken, H.**, An entirely humanized CD3 zeta-chain signaling receptor that directs peripheral blood t cells to specific lysis of carcinoembryonic antigen-positive tumor cells. *Int J Cancer* 2000. **88**: 115-120.
- 94 **Hombach, A., Heuser, C., Marquardt, T., Wiczarkowicz, A., Groneck, V., Pohl, C. and Abken, H.**, CD4+ T cells engrafted with a recombinant immunoreceptor efficiently lyse target cells in a MHC antigen- and Fas-independent fashion. *J Immunol* 2001. **167**: 1090-1096.
- 95 **Harder, T. and Kuhn, M.**, Immunoisolation of TCR signaling complexes from Jurkat T leukemic cells. *Sci STKE* 2001. **2001**: PL1.
- 96 **Sambrook, J., Fritsch, E. F. and Maniatis, T.**, *Molecular Cloning, A Laboratory Manual*, 2nd ed. Edn. Cold Spring Harbor (N.Y.) Laboratory Press: 1989.
- 97 **Bonifacio, J.**, Biosynthetic Labeling of Proteins. In **John E. Coligan, A. M. K., David H. Margulies, Ethan M. Shevach, Warren Strober** (Ed.) *Current Protocols in Immunology*. John Wiley & Sons, Inc. 1991, pp 8.12.11 - 18.12.19.
- 98 **Altin, J. G. and Pagler, E. B.**, A one-step procedure for biotinylation and chemical cross-linking of lymphocyte surface and intracellular membrane-associated molecules. *Anal Biochem* 1995. **224**: 382-389.
- 99 **Doering, T., Englund, P. and Hart, G.**, Detection of Glycophospholipid Anchors on Proteins. In **Frederick M. Ausubel, R. B., Robert E. Kingston, David D. Moore, J.G. Seidman, John A. Smith, and Kevin Struhl** (eds.) (Ed.) *Current Protocols in Molecular Biology*. John Wiley & Sons, Inc. 1993, pp 17.18 ff.
- 100 **Butschak, G. and Karsten, U.**, Isolation and characterization of thomsen-friedenreich-specific antibodies from human serum. *Tumour Biol* 2002. **23**: 113-122.
- 101 **Woodward, M. P., Young, W. W., Jr. and Bloodgood, R. A.**, Detection of monoclonal antibodies specific for carbohydrate epitopes using periodate oxidation. *J Immunol Methods* 1985. **78**: 143-153.
- 102 **Kroczek, R. A. and Siebert, E.**, Optimization of northern analysis by vacuum-blotting, RNA-transfer visualization, and ultraviolet fixation. *Anal Biochem* 1990. **184**: 90-95.
- 103 **Han, J. H., Choi, S. J., Kurihara, N., Koide, M., Oba, Y. and Roodman, G. D.**, Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. *Blood* 2001. **97**: 3349-3353.
- 104 **Hollenbaugh, D., Aruffo, A., Jones, B. and Linsley, P.**, Use of Monoclonal Antibodies for Expression Cloning. In **Frederick M. Ausubel, R. B., Robert E. Kingston, David D. Moore, J.G. Seidman, John A. Smith, and Kevin Struhl** (eds.) (Ed.) *Current Protocols in Molecular Biology*. John Wiley & Sons, Inc. 1994, pp 6.11.11 - 16.11.15.
- 105 **Kaufman, R. J.**, Overview of Protein Expression in Mammalian Cells. In **Frederick M. Ausubel, R. B., Robert E. Kingston, David D. Moore, J.G. Seidman, John A. Smith, and Kevin Struhl** (eds.) (Ed.) *Current Protocols in Molecular Biology*. John Wiley & Sons, Inc. 1994, pp 6.12.11 - 16.12.16.
- 106 **Aruffo, A.**, Transient Expression of Proteins Using COS Cells. In **Frederick M. Ausubel, R. B., Robert E. Kingston, David D. Moore, J.G. Seidman, John A. Smith, and Kevin Struhl** (eds.) (Ed.) *Current Protocols in Molecular Biology*. John Wiley & Sons, Inc. 1994, pp 16.13.11 - 16.13.17.
- 107 **Wysocinski, L. J. and Sato, V. L.**, "Panning" for lymphocytes: a method for cell selection. *Proc Natl Acad Sci U S A* 1978. **75**: 2844-2848.
- 108 **Hirt, B.**, Selective extraction of polyoma DNA from infected mouse cell cultures. *J Mol Biol* 1967. **26**: 365-369.
- 109 **Gluzman, Y.**, SV40-transformed simian cells support the replication of early SV40 mutants. *Cell* 1981. **23**: 175-182.
- 110 **Gulick, T.**, Transfection Using DEAE-Dextran. In **Frederick M. Ausubel, R. B., Robert E. Kingston, David D. Moore, J.G. Seidman, John A. Smith, and Kevin Struhl** (Ed.) *Current Protocols in Molecular Biology*. John Wiley & Sons, Inc. 1994, pp 9.2 ff.

- 111 **Hombach, A., Koch, D., Sircar, R., Heuser, C., Diehl, V., Kruis, W., Pohl, C. and Abken, H.**, A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA. *Gene Ther* 1999. **6**: 300-304.
- 112 **Weijens, M. E., Willemsen, R. A., Hart, E. H. and Bolhuis, R. L.**, A retroviral vector system 'STITCH' in combination with an optimized single chain antibody chimeric receptor gene structure allows efficient gene transduction and expression in human T lymphocytes. *Gene Ther* 1998. **5**: 1195-1203.
- 113 **Hasbold, J., Gett, A. V., Rush, J. S., Deenick, E., Avery, D., Jun, J. and Hodgkin, P. D.**, Quantitative analysis of lymphocyte differentiation and proliferation in vitro using carboxyfluorescein diacetate succinimidyl ester. *Immunol Cell Biol* 1999. **77**: 516-522.
- 114 **Butschak, G., Harborth, J., Osborn, M. and Karsten, U.**, New monoclonal antibodies recognizing phosphorylated proteins in mitotic cells. *Acta Histochem* 1995. **97**: 19-31.
- 115 **Barlogie, B., Shaughnessy, J., Tricot, G., Jacobson, J., Zangari, M., Anaissie, E., Walker, R. and Crowley, J.**, Treatment of multiple myeloma. *Blood* 2004. **103**: 20-32.
- 116 **Morgan, G. J. and Davies, F. E.**, Evolving treatment strategies for myeloma. *Br J Cancer* 2005. **92**: 217-221.
- 117 **Hakomori, S.**, Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. *Cancer Res* 1996. **56**: 5309-5318.
- 118 **Mattes, M. J.**, Binding parameters of antibodies: pseudo-affinity and other misconceptions. *Cancer Immunol Immunother* 2005. **54**: 513-516.
- 119 **Mattes, M. J.**, Binding parameters of antibodies reacting with multivalent antigens: functional affinity or pseudo-affinity. *J Immunol Methods* 1997. **202**: 97-101.
- 120 **Real, F. X., Mattes, M. J., Houghton, A. N., Oettgen, H. F., Lloyd, K. O. and Old, L. J.**, Class 1 (unique) tumor antigens of human melanoma. Identification of a 90,000 dalton cell surface glycoprotein by autologous antibody. *J Exp Med* 1984. **160**: 1219-1233.
- 121 **Carey, T. E., Lloyd, K. O., Takahashi, T., Travassos, L. R. and Old, L. J.**, AU cell-surface antigen of human malignant melanoma: solubilization and partial characterization. *Proc Natl Acad Sci U S A* 1979. **76**: 2898-2902.
- 122 **Mattes, M. J., Cordon-Cardo, C., Lewis, J. L., Jr., Old, L. J. and Lloyd, K. O.**, Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies. *Proc Natl Acad Sci U S A* 1984. **81**: 568-572.
- 123 **Desai, P. R., Ujjainwala, L. H., Carlstedt, S. C. and Springer, G. F.**, Anti-Thomsen-Friedenreich (T) antibody-based ELISA and its application to human breast carcinoma detection. *J Immunol Methods* 1995. **188**: 175-185.
- 124 **Meichenin, M., Rocher, J., Galanina, O., Bovin, N., Nifantev, N., Sherman, A., Cassagnau, E., Heymann, M. F., Bara, J., Fraser, R. H. and Le Pendu, J.**, Tk, a new colon tumor-associated antigen resulting from altered O-glycosylation. *Cancer Res* 2000. **60**: 5499-5507.
- 125 **Smorodin, E. P., Kurtenkov, O. A., Sergeyev, B. L., Pazynina, G. V. and Bovin, N. V.**, Specificity of human anti-carbohydrate IgG antibodies as probed with polyacrylamide-based glycoconjugates. *Glycoconj J* 2004. **20**: 83-89.
- 126 **Bovin, N. V.**, Polyacrylamide-based glycoconjugates as tools in glycobiology. *Glycoconj J* 1998. **15**: 431-446.
- 127 **Van Lenten, L. and Ashwell, G.**, Studies on the chemical and enzymatic modification of glycoproteins. A general method for the tritiation of sialic acid-containing glycoproteins. *J Biol Chem* 1971. **246**: 1889-1894.
- 128 **Hamburger, J., Lustigman, S., Siongok, T. K., Ouma, J. H. and Mahmoud, A. A.**, Characterization of a purified glycoprotein from *Schistosoma mansoni* eggs: specificity, stability, and the involvement of carbohydrate and peptide moieties in its serologic activity. *J Immunol* 1982. **128**: 1864-1869.
- 129 **Hakomori, S. and Kannagi, R.**, Glycosphingolipids as tumor-associated and differentiation markers. *J Natl Cancer Inst* 1983. **71**: 231-251.
- 130 **Hart, G. W.**, Putative Functions of GPI Anchors. In **Ajit Varki, R. C., Jeffrey Esko, Hudson Freeze, Gerald Hart, Jamey Marth** (Ed.) *Essentials of Glycobiology*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York 1999.
- 131 **Simons, K. and Ikonen, E.**, Functional rafts in cell membranes. *Nature* 1997. **387**: 569-572.
- 132 **Hombach, A., Heuser, C., Sircar, R., Tillmann, T., Diehl, V., Kruis, W., Pohl, C. and Abken, H.**, T cell targeting of TAG72+ tumor cells by a chimeric receptor with antibody-like specificity for a carbohydrate epitope. *Gastroenterology* 1997. **113**: 1163-1170.
- 133 **Hwu, P., Shafer, G. E., Treisman, J., Schindler, D. G., Gross, G., Cowherd, R., Rosenberg, S. A. and Eshhar, Z.**, Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. *J Exp Med* 1993. **178**: 361-366.